Actinium Pharmaceuticals is focused on developing highly differentiated and innovative first-in-class product candidates. Our current pipeline of clinical and preclinical stage targeted radiotherapy product candidates including Actimab-A, ATNM-400 and Iomab-ACT are directed against validated cancer targets for indications in hematology, solid tumors and conditioning for cell and gene therapies, which we believe have high unmet needs that are not addressed by currently available treatment options.
